A New Class of Cancer Therapy
Gene therapy for cancer
We rewrite the tumor genome, turning cancer cells into factories for their own destruction.
Scroll
We rewrite the tumor genome, turning cancer cells into factories for their own destruction.
Our Trojan-RNA™ carries special engineered motifs that act as a molecular switch, off by default. A cancer-specific protein binds the motif and flips the switch on, driving insertion of the RNA into the genome.
Cancer-specific proteinthe trigger
the switchRNA motif
OFF
ON
The same RNA reaches every cell, but only cancer cells switch it on.
Drug is produced only inside the tumor, so potent cytokines like IL-12, too toxic to give systemically, become usable.
The payload integrates into the cancer genome for durable local production, instead of a dose that fades within days.
The switch is present across roughly half of human cancers, building patient selection into the biology, and one chassis fits many payloads.
Weizmann Institute of Science. Former VP, Emendo Bio. 9+ years of senior biopharma R&D leadership, from discovery to strategic deal preparation.
Tel Aviv University. Former Director, Emendo Bio. 6+ years leading multidisciplinary R&D, protein discovery, biochemistry, and high-throughput assays.
Former head of the Technion Integrated Cancer Center, President of the International Cancer Microenvironment Society, and Vice Dean for Research at the Rappaport Faculty of Medicine. An entrepreneur and consultant in cancer therapy.
Raphael is a scientist, entrepreneur, and angel investor with 30+ years commercializing recombinant cytokines and pre-clinical contract research services. Co-Founder of two preclinical CROs and four biotech companies: Karyopharm Therapeutics (Nasdaq: KPTI), Galectin Sciences, VuJa De Sciences, and Alma BioTherapeutics, as well as SBH Diagnostics.
We're raising $3M to reach our lead RNA molecule. We'd welcome a conversation with investors and partners.
